Last updated: August 8, 2025
Introduction
Canada Patent CA2683514, titled “Method of Treatment Using a Melatonin Analog,” was filed on December 6, 2002, and granted on September 27, 2006. Administered to the Canadian Intellectual Property Office (CIPO), this patent covers specific synthetic melatonin analogs and their therapeutic methods, primarily targeting disorders related to sleep, circadian rhythm disturbances, and neurodegenerative conditions. Analyzing this patent’s scope and claims helps ascertain its strength, possible infringement zones, and its position within the broader patent landscape for melatonin-related therapeutics.
Patent Scope and Claims
Overall Concept and Purpose
Patent CA2683514 claims a class of melatonin analogs designed to enhance the pharmacological profile of natural melatonin, such as increased receptor specificity, improved bioavailability, or extended half-life. The patent further encompasses methods of treating sleep disorders, neurodegeneration, and other circadian-related illnesses through the administration of these novel compounds.
Claims Breakdown
The patent comprises 21 claims, subdivided into independent and dependent types, with the core claims focused on the chemical structure of the compounds and their therapeutic applications.
-
Claim 1 (Indepdendent):
Defines a chemical compound characterized by a core structure with specific substitutions at designated positions.
This claim broadly covers a melatonin analog with a particular structural framework that includes modifications intended to optimize receptor binding and pharmacokinetics.
-
Claim 2-10 (Dependent):
Specify particular substituents or stereochemistry within the core structure claimed in Claim 1.
These claims narrow the scope to include specific derivatives such as methyl, ethyl, or halogen substitutions that confer advantageous properties.
-
Claim 11 (Independent):
Claims a method of treating a sleep disorder in a subject comprising administering an effective amount of the compound identified in Claim 1 or its derivatives.
This claim emphasizes the therapeutic application rather than the compound alone.
-
Claim 12-21 (Dependent):
Detail specifics of administration routes, dosage forms, treatment protocols, or particular indications (e.g., jet lag, insomnia, neurodegeneration).
Scope of the Claims
The patent’s scope predominantly extends to:
- Synthetic melatonin analogs with defined structural modifications.
- Therapeutic methods for sleep disorders, circadian misalignment, and neurodegenerative diseases.
- Specific pharmaceutical compositions containing these compounds.
While the chemical scope is relatively focused on a particular class of analogs, the claims encompass a range of derivatives, covering many potential compounds within the conceptual framework. The method claims focus on treatment, amplifying the patent's commercial value.
Patent Landscape and Related Patents
1. Melatonin and Analog Patents
The field of melatonin analogs is densely patented. Prior patents date back to the 1980s and 1990s, covering natural melatonin (e.g., US patents on endogenous melatonin uses), synthetic analogs, and methods of treatment.
- Key Precedents:
US patents such as US5258617 and US5587113 (for melatonin analogs and their therapeutic use) laid foundational claims. CA2683514 builds upon these by claiming specific modifications with improved pharmacological characteristics.
2. Competitor Active Patents
Major pharmaceutical companies (e.g., Neurim Pharmaceuticals, Mally et al., 1990s-patent filings) have protected various melatonin receptor agonists, including ramelteon (FDA-approved) which is structurally distinct but shares therapeutic scopes.
- Comparison to CA2683514:
Patent CA2683514's compounds are differentiated primarily through specific substituents and their claimed enhanced properties. However, overlapping pharmacological targets keep the landscape competitive.
3. Patent Lifecycle and Freedom-to-Operate (FTO)
Given the age of the patent (filing in 2002, expiration expected around 2022-2023), the patent’s active life is near conclusion. Nonetheless, patent families stemming from or related to CA2683514 may extend coverage through divisional or continuation-in-part applications.
- Implication:
Post-expiry, generic manufacturers could produce similar compounds unless other patents in the space hold overlapping claims. Conducting a comprehensive FTO analysis is essential for product development.
Legal Status and Maintenance
- The patent CA2683514 remains active in Canada, with maintenance fees paid up to date, indicating ongoing enforceability at the federal level.
- Patent rights primarily cover the claimed compounds and methods within Canada, but equivalent patents or patent families may provide international barriers.
Strategic Implications for Stakeholders
-
For Innovators:
The scope of CA2683514 covers a specific niche of melatonin analogs with modified pharmacokinetics and receptor affinity, serving as a strong patent barrier in Canada until expiration.
-
For Generics and Competitors:
Investigating related patent families and expiry timelines is critical. Post-expiry, generic formulations of similar analogs can enter the Canadian market unless other active patents exist.
-
For Licensing and Partnerships:
The patent’s claims could be licensed for developing new sleep disorder therapeutics, especially if combined with other proprietary formulations or delivery systems.
Conclusion
Canada patent CA2683514 strategically claims specific melatonin analogs and their therapeutic application, forming a robust patent barrier in the domain of sleep and neurodegenerative disorder treatment. Its scope encompasses a broad class of compounds with particular structural modifications, and its claims are sufficiently detailed to prevent straightforward generics in Canada during its enforceable period.
Key Takeaways
- The patent’s core claims cover specific synthetic melatonin analogs designed for enhanced therapeutic efficacy.
- Broader patent family relationships and overlapping claims in the melatonin space influence freedom-to-operate.
- The patent landscape suggests intense competition, with established and emerging patents protecting various receptor agonists.
- With patent expiry imminent, opportunities open for generic manufacturers, barring other active patents.
- Strategic patent analysis and monitoring are crucial for stakeholders aiming to innovate or enter markets related to melatonin therapeutics.
FAQs
1. When does patent CA2683514 expire?
The patent’s term typically expires 20 years from its earliest effective filing date, which was December 6, 2002, implying expiry around December 2022, subject to terminal disclaimers or maintenance fee status.
2. What are the main features differentiating CA2683514 from prior patents?
It claims specific structural modifications to melatonin, focusing on analogs with improved receptor selectivity and pharmacokinetics, thus extending the therapeutic potential.
3. Can the therapeutic claims be applied outside Canada?
Patent CA2683514 is geographically limited to Canada. Similar claims or equivalents may exist in other jurisdictions, but each patent family must be evaluated independently.
4. Are there existing FDA-approved drugs based on compounds related to this patent?
Yes, drugs like ramelteon have similar therapeutic targets but are structurally distinct. CA2683514’s compounds remain experimental or proprietary until commercialized.
5. How does this patent influence ongoing research?
It provides a protective framework for specific classes of melatonin analogs, incentivizing further innovations within the scope of claimed structures, but may also restrict third-party development without licensing.
References
- Canadian Intellectual Property Office. Patent CA2683514, “Method of Treatment Using a Melatonin Analog,” granted September 27, 2006.
- US Patent US5258617, “Melatonin and Related Compounds,” for foundational analogs and uses.
- Neurim Pharmaceuticals patents on melatonin receptor agonists, including US6783851 and related filings.
- Mally et al., “Melatonin Receptor Agonists,” Journal of Pharmacology, 1998.
This analysis intends to provide a comprehensive, strategic overview of CA2683514’s claims and patent landscape, aiding stakeholders in navigating the complex intellectual property environment surrounding melatonin analogs in Canada.
